Mycophenolic acid (MPA) is an important immunosuppressant broadly used in renal transplantation. However, the large inter-patient variability in mycophenolic acid (MPA) pharmacokinetics (PK) limits its use. We hypothesize that extrahepatic metabolism of MPA may have significant impact on MPA PK variability. Two intestinal UDP-glucuronosyltransferases 1A8 and 1A10 plays critical role in MPA metabolism. Both in silico and previous genome-wide analyses suggested that vitamin D (VD) may regulate intestinal UGT1A expression. We validated the VD response elements (VDREs) across the UGT1A locus with chromatin immunoprecipitation (ChIP) and luciferase reporter assays. The impact of 1-alpha,25-dihydroxyvitamin D3 (D3) on UGT1A8 and UGT1A10 transcription and on MPA glucuronidation was tested in human intestinal cell lines LS180, Caco-2 and HCT-116. The correlation between transcription levels of VD receptor (VDR) and the two UGT genes were examined in human normal colorectal tissue samples (n 5 73). PK alterations of MPA following the parent drug, mycophenolate mofetil (MMF), and D3 treatment was assessed among renal transplant recipients (n 5 10). Our ChIP assay validate three VDREs which were further demonstrated as transcriptional enhancers with the luciferase assays. D3 treatment significantly increased transcription of both UGT genes as well as MPA glucuronidation in cells. The VDR mRNA level was highly correlated with that of both UGT1A8 and UGT1A10 in human colorectal tissue. D3 treatment in patients led to 
INTRODUCTION
Mycophenolate mofetil (MMF) is increasingly used as an important immunosuppressant to prevent acute rejection after kidney transplantation. Recent clinical studies have consistently suggested that including MMF is superior to other immunosuppressant combinations in maintaining renal function, in the development of adverse effects, as well as in graft and patient survival. [1] [2] [3] [4] However, inter-patient variability in its pharmacokinetics (PK) limits its full potential in clinical applications. 5, 6 MMF is a prodrug which is hydrolyzed into its active form mycophenolic acid (MPA) after oral intake. 5 It has been shown that the extent of MPA exposure is highly correlated with acute allograft rejection. 7 About 20% of patients discontinue the medication due to the adverse events such as gastrointestinal disorders and bone marrow suppression which were suggested to be associated with the free MPA fraction. 7, 8 In spite of numerous studies to date, the mechanism underlying this inter-patient PK variability of MMF/MPA has not been completely elucidated. 6 In order to individualize the MMF dosage, current MMF administration protocols increasingly apply therapeutic drug monitoring (TDM). 7, 9 Therefore, identifying factors affecting MMF/MPA PK is of particular importance to achieve more effective and safer use of this drug.
Inter-patient PK variability are largely attributed to the variable activities of drug metabolism pathways. Previous studies have demonstrated that MPA is mainly metabolized via glucuronidation by UDPglucuronosyltransferases (UGTs) in both the liver and intestine, which produces a major phenolic glucuronide, mycophenolic acid glucuronide (MPAG), and a minor acyl glucuronide (AcMPAG). [10] [11] [12] [13] [14] UGTs catalyze the formation of hydrophilic glucuronides, which is one of the important detoxification processes in human metabolism. 15 The human UGTs consists of 4 families, UGT1, UGT2A and 2B, UGT3, and UGT8, of which, UGT1, UGT2A and UGT2B are primarily involved in drug metabolism and are encoded by genes located on chromosome 2 and 4, respectively. [15] [16] [17] Variability in UGT activity has been significantly associated with inter-individual differences in metabolism of a broad array of endogenous and exogenous compounds including many therapeutic agents. 18 Previous studies have revealed that glucuronidation of MPA mainly involves UGT1A8 and UGT1A9, with UGT1A10 and UGT2B7 playing a minor role. [10] [11] [12] [13] [14] While UGT1A9 and UGT2B7 are important hepatic UGTs whose roles in MPA metabolism have been widely investigated, UGT1A8 and UGT1A10 are the only two UGT1A enzymes expressed in human intestinal tissue including the small intestine, colon and rectum, 15, 19 and their roles in MPA PK variability has drawn only limited attention. It has been suggested that intestinal UGTs are also critical to the metabolism of many AT A GLANCE COMMENTARY Wang X, et al.
Background
Mycophenolic acid (MPA) is an important immunosuppressant, but the large inter-patient variability in its pharmacokinetics (PK) limits its use. Our study found that 1-alpha,25-dihydroxyvitamin D3 (VD) regulates the transcription of two intestinal UDP-glucuronosyltransferases UGT1A8 and UGT1A10 which are involved in glucuronidation of MPA, which has a significant impact on MPA pharmacokinetics in kidney transplant recipients.
Translational Significance
Our study identified a novel mechanism underlying the inter-patient variability in MPA pharmacokinetics, and suggests co-administration of VD with MPA may potentially result in drug-drug interaction and lead to inter-and intra-patient difference in clinical response to MPA treatment.
compounds. 20, 21 Therefore, variability in the activities of these two enzymes may also significantly contribute to the inter-patient difference in both the pharmacokinetics and pharmacodynamics of MMF/ MPA.
On the other hand, as one of the most important transcription factors in human intestinal tissue, the vitamin D receptor (VDR) plays a crucial role in regulating a large number of genes. 22, 23 A recent genome-wide study using a human intestinal cell line LS180 revealed that UGT1A locus harbors multiple vitamin D response elements (VDREs), and UGT1A gene expression is significantly induced by 1-alpha,25-dihydroxyvitamin D 3 [1a,25(OH) 2 D 3 ] treatment. 24 Given that only 1 cell line was tested in this study, additional VDREs may also exist e.g. in a cell-specific manner, we further performed an in silico screening for putative VDREs (the most common DR3-type) 25 in the UGT1A8 and UGT1A10 region as well as the entire UGT1A locus. We have identified a number of putative VDREs in this region. On the other hand, our previous study has suggested that VDR is not a significant regulator for hepatic UGTs, further underscores the importance of potential VDR-UGT regulation in intestinal tissues. We therefore hypothesize that VD/VDR is an important regulator for intestinal UGTs 1A8 and 1A10, which may further influence the MPA metabolism. In order to corroborate this hypothesis, we performed studies in human colorectal cancer cell lines and tissue samples aiming to: 1) validate the binding of VDR to the putative VDREs; 2) examine the effects of 1a,25(OH) 2 D 3 treatment in regulating UGT1A8 and UGT1A10 mRNA expression and enzyme activity in MPA glucuronidation; and 3) examine the effects of 1a,25(OH) 2 D 3 on MMF/MPA PK profiles in human kidney transplantation patients.
METHODS
Human tissue samples and kidney transplantation patients. Human colorectal (n 5 73) mucosa tissue samples were collected at the time of surgery from pathologically documented colorectal cancer patients at the Shanghai First People's Hospital (Shanghai, China) with informed consent and conformation with institutional guidelines. All collected normal tissue were .5 cm away from the primary tumor site. The patients are all Han Chinese in origin with a median age of 68 years, and 50% of whom were female.
Kidney transplantation recipients (n 5 10) were recruited to test the impact of vitamin D on the MPA PK profiles. Patient information was summarized in 24 or 48 hrs, followed by co-incubation with MPA (2 mM) and UDPGA (0.5 mM) for additional 4 hrs. MPA glucuronidation rates were measured using HPLC/MS/MS. Briefly, the peak areas of MPA and MPAG were calculated and the ratio of MPAG/MPA were normalized to the mean values of the ratios of triplicates. These normalized ratios were then reported as the endpoint data. Assays were performed in triplicates and repeated twice. (See details in supplement methods).
Effect of 1a,25(OH) 2 D 3 treatment on MPA PK profiles in vivo. We recruited kidney transplantation recipients (n 5 10) who all underwent kidney transplantation 14-15 days prior to the PK study. Baseline Creatinine, Creatinine Clearance (CrCL) and albumin levels for all patients were collected (Table SII) . Cyclosporine A (CsA) and prednisone were administrated for all patients, with the CsA C0 and Cmax maintained at 200-250 ng/ML and 1200-1500 ng/ML, respectively for every patient and prednisone for 16 mg PO, q.d.
MMF (Hoffman-La Roche) (1 g/dose, every 12 hrs) was administrated to all patients for one week. Plasma MPA concentrations were monitored on day 8 for 12 hrs. MMF (same dose as aforementioned) and Rocaltrol (Calcitriol, Hoffman-La Roche) (0.25 mg/dose, once daily) were co-administrated to the patients for additional one week. On day 16, plasma MPA concentrations were measured again at the same time points as in day 8 for 12 hrs. The experimental design was summarized in Fig. S3 . Patients were screened by physical examination and detailed laboratory tests were conducted if necessary. Patients who had co-morbid disease or liver function that deviated from the normal range were excluded from the study. All enrolled patients did not smoke or drink alcohol, and were instructed to maintain a regular diet during the trial without any use of supplements, Chinese medicine or other treatments.
Quantification of plasma MPA was conducted by mixing patient plasma sample (20 mL) and acetonitrile (800 ml) containing internal standard (osalmid, 96 ng/ ml), followed by centrifugation 12000 rpm for 10 min. The supernatant was used to detect MPA using LC-MS/MS with similar settings as mentioned above.
Pharmacokinetic analysis. Pharmacokinetic parameters were estimated using a noncompartmental analysis. The maximum serum MPA concentrations (Cmax) and time to reach Cmax (Tmax) were determined by visual inspection of the serum MPA concentration-time curves. The terminal elimination rate constant (k) was calculated by least-squares linear regression of the log-linear portion of the serum concentration-time curves. The area under the serum concentration-time curve from 0 to 12 hours (AUC 0-12 ) was calculated using the linear trapezoidal rule. Since MMF is rapidly and completely hydrolyzed to MPA, the oral clearance (CL/F) of MPA was estimated by the ratio of the MMF dose (corrected for differences in the molecular weight) and the AUC of the dosing interval.
Data analyses and statistics. Comparison between treatments in cell lines was conducted using an unpaired t-test. The correlation between VDR and UGT gene expression was performed with linear regression. A paired t-test was used to compare the difference in PK parameters before and after vitamin D treatment in transplantation patients. The type I error rate was set to 0.05 for all comparisons. Data were analyzed and plotted using Graphpad InStat 3.0 and Prism 6.0, respectively (CA, USA).
RESULTS
Identification and confirmation of the VDREs in the UGT1A region. Our bioinformatic analysis of 200 kb region of the entire UGT1A locus reveals a total of 83 putative DR3-type VDREs in the region, with 13 of which distributed within the UGT1A8-UGT1A10 6 10kb region (see supplemental Table SI for more details). However, the two ChIP-seq identified VDREs were not predicted in our list, suggesting that they might be motifs that are different from DR3-type.
To validate these VDR binding sites, we used three human colorectal cancer cell lines: LS180, Caco-2 and HCT-116. We first conducted ChIP assays for the two ChIP-seq identified VDREs (CS1 and CS2) as well as 4 putative VDREs (No. 16, 17, 21 and 22) closest to the UGT1A8 or UGT1A10 exon 1 region (Table SI) . Positive binding of VDR to the locus 16 (VDRE16) (approximately 5.5kb upstream from UGT1A8 exon 1, Chr 2: 234,520,791-234,520,805) was observed in all 3 cell lines especially at the time point of 24 hr (Fig 1A) . Both ChIP-seq identified VDR binding regions showed strong VDR binding after 24 hrs of vitamin D treatment in LS180 (Fig 1B) but not in Caco-2 or HCT-116 (Fig. S2) . No significant binding of VDR to the remaining 3 tested loci (17, 21 and 22) has been observed (data not shown).
Cloning and luciferase assay. To further validate the D3 regulation on UGT1A8 and UGT1A10 gene expression, we respectively cloned the three DNA fragments (CS1, CS2 and VDRE16) into the upstream region of Data were shown as mean 6 SD for each treatment group. The ratio of expression level between each UGT relative to that of the 18S gene was normalized to that of the control group. *P , 0.05; **P , 0.01. P values were calculated based on the comparison between the 1a,25(OH) 2 D 3 treatment group and control group. Transcription levels of both UGT1A8 and UGT1A10 were not detectable in HCT-116 before and after 1a,25(OH) 2 D 3 treatment and therefore were not shown. The ratio between MPAG and MPA levels was normalized to that of the control group. Data were shown as mean 6 SD for each treatment group. *P , 0.05; **P , 0.01. P values were calculated based on the comparison between the 1a,25(OH) 2 D 3 treatment group and control group for each cell line. the SV40 promoter of the pGL3-promoter vector. Transient transfection of all three constructs into the LS180 demonstrated that these VDR binding sites significantly enhanced the reporter gene promoter activity under 1a,25(OH) 2 D 3 treatment as compared to the pGL3-Promoter vector or the control group with vehicle only. The luciferase activity was increased about 40-60% in these cells after 1a,25(OH) 2 D 3 treatment (P , 0.05 for all tests) (Fig 2) .
Induction of UGT1A8 and UGT1A10 expression by 1a,25(OH) 2 D 3 treatment. We then tested whether the transcription of both UGT genes was inducible by 1a,25(OH) 2 D 3 . After treatment of all 3 cells with 1a,25(OH) 2 D 3 for 24 hrs, significantly increased expression of both UGT1A8 and UGT1A10 was observed in LS180 and Caco-2 but not in the HCT-116 cell line (Fig 3) . The induction of both UGT1A8 and UGT1A10 was dose-dependent in Caco-2 and LS180, respectively, with significantly increased expression of both genes observed in both cell lines under the higher concentration (10 28 M) (P , 0.05 for all tests). Real-time PCR analysis demonstrated that both UGT genes were not detectable in HCT-116 cell lines with or without any treatment (data not shown).
Regulation of MPA glucuronidation activity in vitro by 1a,25(OH) 2 D 3 . We further examined whether MPA metabolism is altered after 1a,25(OH) 2 D 3 induction for UGT1A8 and UGT1A10 expression. All 3 cells were treated with 1a,25(OH) 2 D 3 for 24 hrs or 48 hrs and the MPA glucuronidation product MPA glucuronide (MPAG) was measured. We found that MPA glucuronidation activity in both Caco-2 and LS180 was significantly increased 1.6-and 2.5-fold after 48 hrs of induction, respectively (P , 0.002), but not in the HCT-116 cells (P 5 0.22) (Fig 4) , which is consistent with the induction results for the transcription of two UGTs by 1a,25(OH) 2 D 3 among these 3 cells.
Gene expression of VDR, UGT1A8 and UGT1A10 genes in human colorectal tissue. In order to examine whether the VDR regulation for both UGT genes also exists in vivo, we quantified the mRNA levels of all three genes in a set of normal colorectal tissue samples (n 5 73). We found that all three genes were highly expressed in human colorectal tissue. There was a highly significant positive correlation in the expression level between VDR and the UGT1A8 (r 5 0.49, P , 0.0001) or UGT1A10 (r 5 0.77, P , 0.0001) gene (Fig 5) . by about 40% in these patients (P 5 0.0008 and P 5 0.003, respectively), while the oral clearance (CL/F) of MPA was significantly increased over 70% (P 5 0.008) (Fig 6) . No statistically significant relationships were observed between age, gender, BMI or weight with these parameters (P . 0.05, data not shown). Effect of other clinical factors including Cr, CrCL and Albumin levels on PK parameter changes were also tested and no statistically significant impact were observed (P . 0.05, data not shown). 
DISCUSSION
Our study for the first time demonstrates that vitamin D significantly alters the metabolism of MPA by modulating the expression of two intestinal UGTs in vitro. This effect may further lead to an altered MPA pharmacokinetics when MPA and vitamin D are coadministrated. This modulation may in part explain the inter-and intra-individual differences in MPA PK observed clinically. More importantly, our findings have critical clinical implications. Previous studies have indicated that the MPA PK parameters are significantly associated with various clinical outcomes in renal transplant recipients as well as adverse events. 4, 6, 7 This calcitriol-MPA interaction, especially during calcitriol co-administration or dietary supplementation may potentially reduce the efficacy of MMF and increase the risk of organ rejection. This is particularly an issue as osteoporosis e.g. bone loss and fracture, is a common and serious morbidity in kidney transplantation, and calcitriol is increasingly used to reduce the accelerated bone loss in renal transplant recipients. 26, 27 Understanding the inter-individual variability in the gene expression of drug metabolism enzymes in different tissues or organs is tremendously important for individualizing medication. Compared to hepatic UGTs, there are very limited studies on the genetic basis for the regulation of UGT1A8 and UGT1A10, which are predominantly expressed in human intestinal tissue. 15, 19 Our study suggests that intestinal regulation of UGT genes is also important in the pharmacokinetics of therapeutic agents. Although other UGTs e.g. UGT1A9 and UGT2B7 were also shown to be involved in MPA glucuronidation, [10] [11] [12] [13] [14] our previous study demonstrated that VDR is not a significant regulator for hepatic UGTs. 28 This suggests that this vitamin D-UGT modulation may be tissue-specific. It is now important to consider both the hepatic and extrahepatic metabolism in order to completely understand the inter-patient variability in MPA PK and/or efficacy. In addition, given the numerous therapeutic agents that are substrates of UGT1A8 and/or UGT1A10, 18, 21, [29] [30] [31] [32] [33] [34] we suggest that caution should be exercised when vitamin D is co-administered.
Given the large number of in silico-predictive putative VDREs at the UGT1A locus, we did not validate all of them in our study. Rather, we focused our validation on the putative VDREs closest to the UGT1A8 and UGT1A10 regions. Our subsequent in vitro and ex vivo assays strongly suggested that intestinal UGT1A8 and UGT1A10 are VD-regulated genes. This finding is consistent with the recent genome-wide ChIP-seq study by Meyer MB et al, 24 where VDR binding sites were identified in the UGT1A region and UGT1A transcription was significantly induced by vitamin D treatment in the LS180 cell. However, the VDRE16 identified in our study was not observed in this ChIP-seq assay in LS180, and our confirmatory assay also did not observe the two loci identified in their study in Caco-2 and HCT-116 cells. While this may be due to the different cell lines used which further reflects a potential cellspecific usage of the VDREs, it also suggests that additional types of VDREs are located in the region since no DR3-type of VDRE was predicted in the two loci identified by the ChIP-seq. Further analyses are now ongoing in the lab to elucidate the detailed VDR binding mechanism to these VDREs. Nevertheless, our results combined with the findings in Meyer's study provide evidence that multiple VDREs may be distributed in the entire locus. As ChIP-seq has been the unequivocal strategy in identifying transcription factor-binding DNA elements, a comprehensive ChIP-seq analysis in multiple cell lines derived from intestinal tissue under different treatment options may eventually unravel the detailed mechanism underlying the VDR regulation of the two UGTs.
We did not observe induction of either UGT in HCT-116 cells, although the ChIP assay demonstrated a strong VDR binding to the identified VDRE16 in this cell (Fig 2) . An explanation is that additional mechanisms may be involved in the inactivation of the two UGT genes in this cancer cell line. There is no expression of the two UGT genes in the non-treated HCT-116 cells in our real-time PCR assay, which was in contrast to the relatively higher basal expression in the Caco-2 or LS180 cells (data not shown). Interestingly, it has been reported that DNA methylation represses UGT1A1 expression in colon cancer cells, in particular HCT-116. 35, 36 It is thus reasonable that a similar mechanism may be involved in the inactivation of UGT1A8 and UGT1A10 in this cell.
MPA is a widely used and important immunosuppressant medication that requires specific therapeutic levels for optimal clinical efficacy. The potential clinical implications of our findings clearly support more research to further elucidate the regulation of these two UGT enzymes by vitamin D and the VDR. This research is all the more imperative, given the ubiquitous and seemingly innocuous clinical practice of providing vitamin D supplementation to patients.
APPENDIX METHODS Bioinformatic analysis. The entire UGT1A locus and 6100kb flanking region (a total of 352,020 bp) were screened for putative VDREs. Although there are different types of VDREs, we only focused on the most typical DR3 type consensus sequence, i.e. the direct repeat (DR) of the hexameric core sequence RGDKYR (R 5 G or A, D 5 A, G or T, K 5 G or T, Y 5 C or T). 1 The online ''DNA Pattern Find'' program (http://www.ualberta.ca/stothard/javascript/dna_patte rn.html) was used for the motif screening.
Cell culture and treatment with 1a,25(OH) 2 D 3 . Caco-2, HCT-116 and LS180 cell lines were obtained from American Type Culture Collection (Manassas, VA, USA) and maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 50 mg/ml penicillin, 0.25 mg/ml streptomycin, and 2 mM L-glutamine at 37 C with 5% CO 2 .Cells were treated with 1a,25(OH) 2 MPA glucuronidation was quantified using HPLC/MS. Briefly, the sample preparation followed that of Klepacki, et al. 2 In short, protein precipitation was performed using a solution of 30% 0.2 M ZnSO4 in water and 70% methanol. Separation was performed on an Agilent Rapid Res 1200 HPLC system using an Agilent Zorbax XDB-C8 (2.1 3 50 mm, 3.5 mm) column. Mobile phase A was water with 0.1% formic acid and 2 mM NH4Ac. Mobile phase B was 5% water and 95% methanol, with 0.1% formic acid and 2 mM NH4Ac. Gradient elution was used, increasing mobile phase B from 30% to 100% in 10 min. The column was re-equilibrated at 30% B for 5 minutes prior to subsequent injection. A flow rate of 0.3 mL/min was used. Retention time for MPA was 8.8 minutes and for MPAG was 6.7 minutes.
Analytes were quantified by MS/MS utilizing an Agilent 6460 triple quadrupole mass spectrometer with positive electrospray ionization (ESI). A fragmentor energy of 125 V and a dwell time of 150 ms was used. Source parameters were as follows: nitrogen gas temp 5 325 C and flow rate 5 9 L/min, nebulizer pressure 5 35 psi, sheath gas temperature 5 275 C, sheath gas flow rate 5 7 L/min, and capillary potential 5 3.0 kV. Quantitation was based on Multiple Reaction Monitoring (MRM). Maximum sensitivity was obtained by monitoring the corresponding sodium and ammonium adducts, as the protonated adduct response was negligible. 3 Respective adduct responses were summed for calculations. To calculate the MPA-MPAG turnover rate, MPA and MPAG peak areas were quantified. The detection limits (peak area) for MPA and MPAG are 600 and 45, while the MPA and MPAG peak areas in the samples ranged 1 million to 4 million and 2000-50000, respectively. Therefore the peak areas were all well above the detection limits.
Chromatin Immunoprecipitation (ChIP) assay. Caco-2, HCT-116 and LS180 cells were treated with 10 28 M 1a,25(OH) 2 D 3 or vehicle (ethanol) for 1, 8 and 24 hours, respectively. The cells were cross-linked by adding 270 mL formaldehyde to 10 mL medium for 10 min, and the reaction was stopped by 0.125 M glycine (final concentration). Cell lysates were sonicated to generate 200-1,000 bp DNA fragments. Antibodies against VDR (Millipore-Chemicon, MO, USA) were used to immunoprecipitate the DNAprotein complexes. Normal IgG was used as a negative control. After an overnight incubation with the antibody, the immune complexes were collected using 80 mL of protein A Agarose slurry (Upstate Biotechnology, CA, USA). The beads were washed twice with the following buffers (Upstate Biotechnology, CA, USA): low salt washing buffer, high salt wash buffering, LiCl washing buffer, and TE buffer. The DNA was eluted with 1% SDS and 0.1 M NaHCO 3 elution buffer, and then subjected to reverse crosslinking, proteinase digestion, and purification using a commercial kit (Qiagen, Valencia, CA). Among the 83 candidate VDREs, 4 (No. 16, 17, 21, and 22 see Table SI ) were tested for VDR binding. We hypothesized that these 4 loci are the closest to UGT1A8 and UGT1A10 exon 1s, which may possess strongest regulation for these two UGT genes. The primers used to amplify the 4 candidate VDRE regions were 1A8VDRr16-F:
0 , 1A10VDRr21-R: 5 0 -GTGT GGATCCACTTATATGCAG-3 0 ; and 1A10VDRr22-F: 5 0 -CCATCTGCAAGTAATTCCCTTG-3 0 , 1A22VDR r10-R: 5 0 -ACACCAGGTGTTTCATCTGGAT-3 0 . The two VDR binding sites (CS1 and CS2) identified in the recently published ChIP-seq study in LS180 cell 4 were also tested in our samples. These two loci were C for 10s, 56 C for 20s and 72 C for 30s after preheating at 95 C for 10 min. The PCR products were separated and visualized by electrophoresis with 2% Agarose gel. ChIP assays were repeated three times and the representative data are shown. A typical electrophoretic separation of the ChIP-PCR products in agrose gel was shown in Fig. S1 .
Cloning and luciferase assay. The DNA fragment of 185 bp, 330 bp and 178 bp containing VDRE16,CS1-1 and CS2 were generated with PCR and cloned into the pGL-3-Promoter (pGL3-P) vector containing the firefly luciferase gene (Promega, WI, USA). For the CS1 site, we only cloned the CS1-1 fragment as this site was demonstrated to have the strongest VDR binding in the ChIP assay (Fig 1) . Cloned sequences were verified by sequencing. For luciferase assay, the pRL-TK plasmids containing a renilla luciferase gene (Promega) was co-transfected with pGL3-P or pGL3-P-VDRE vectors into LS180 cells, using Lipofectamine 2000 Reagent (Invitrogen, CA, USA) according to manufacturer's instruction. Cells were treated with vehicle (ethanol) or 10 28 M 1a,25(OH) 2 D 3 for 24 hs after the transfection. Cells were then harvested and the firefly and renilla luciferase activities were then measured by using the Dual-Light Luciferase Assay Kit (Promega) according to the manufacturer's instructions. The firefly luciferase activity was normalized to that of the renilla to obtain the relative activity. For plotting the data, all measurements were also normalized to the relative activity value of the pGL3-Ptransfection treated with vehicle only. Experiments were repeated twice and the representative data are shown.
DNA and RNA extraction and reverse transcription. The total RNA of the cells as well as both the RNA and DNA of the human colorectal tissue samples were extracted by using the RNA/DNA Mini Kit (Qiagen, Hilden, Germany). The integrity of the cell and tissue RNA was checked by separated in 1% Agarose gel (Fig. S1) , and concentration was measured by ultraviolet spectroscopy. Complementary DNA (cDNA) was made by reverse transcription of total RNA (1 mg) by using the High-Capacity cDNA Archive Kit (Applied Biosystems, CA, USA).
Real-time PCR. Gene expression levels of UGT1A8, UGT1A10 and/or VDR were quantified with real-time PCR by using the SYBR Green Super Mix (Bio-Rad, CA, USA) in the Eppendorf Realplex real-time PCR system (Eppendorf, Germany) according to the protocol previously established in the lab. 5, 6 Briefly, amplicons in UGT1A8 and UGT1A10 (161 bp and 187 bp, respectively), amplified with primers spanning exon 1 and 2, and VDR (107 bp), sequence spanning exons 6-7, were generated by real-time PCR. The ribosomal 18S rRNA gene and beta-actin gene (ACTB) were used as internal controls. 5, 6 Primer sequences used for the three genes were UGT1A8F: 5 C for 30s after preheating at 95 C for 10 min. The relative expression levels of UGT1A8, UGT1A10 and VDR were normalized by that of 18Sor ACTB, respectively. For each gene, the ratio of its expression relative to 18Sor ACTB was then normalized to that of the sample with the lowest gene expression level.
Real-time PCR for UGT1A8 and UGT1A10 in the induction assay was performed using the same conditions mentioned above. The ratio of UGT gene expression relative to 18S was normalized to that of the cells treated with vehicle only.
Pharmacokinetic analysis in kidney transplantation recipients. Patient information was summarized in Table SII . The experimental design for the clinical investigation was shown in Fig S3. Statistical analyses. Gene expression (relative ratio between each target gene and 18S rRNA or ACTB gene) was log transformed (1log10) prior to the correlation analysis. Comparison of the induction of UGT gene expression as well as luciferase activity between the cells treated with different concentration of 1a,25(OH) 2 D 3 and vehicle only were performed with non-paired t-test. Inter-individual variability in the expression of UGT1A8 and UGT1A10 gene was defined by using the median and distribution range. Correlations between the VDR gene and each UGT gene were performed using Pearson correlation. P 5 0.05 was set as the cut-off for statistical significance. All statistical analysis was performed and plotted using GraphPad Prism version 6.0 for Windows (GraphPad Software, San Diego, CA, USA).
RESULTS
ChIP assay. No significant binding of VDR to the two loci (CS1 and CS2) identified by the previous ChIP-seq study 4 was observed in Caco-2 or HCT-116. Results of the ChIP assays for these loci are shown in Fig. S2 .
Candidate VDREs identified from the UGT1A8-UGT1A10 region. Table SI listed all identified candidate VDERs in the UGT1A locus. These are putative DR3-type VDREs in the UGT1A6100kb region. The core motifs are highlighted in bold. The position of start and end nucleotides of the core motifs on chromosome 2 were based on the human genome assembly hg19 (2009). The four putative VDREs (16, 17, 21 and 22) tested for VDR binding using ChIP assay were highlighted in red. Note that the exon 1 of UGT1A8 and UGT1A10 is between 16 and 17, and 21 and 22, respectively. Time points for blood sample collection 
Translational Research
62.e4 Wang et al December 2016
